NeuroKaire has successfully secured $10 million in funding to advance development of its clinical test which helps identify drug efficacy for depression patients. The funding will help the company scale operations and further expand pharmaceutical partnerships. GreyBird Ventures led the round and the company's other investors include Meron Capital and Jumpspeed Ventures, among others.

NeuroKaire is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company's proprietary and innovative technology helps physicians find the best treatment for their patients. NeuroKaire uses its unique neuronal readout technology to rapidly test approved antidepressants and drug combinations against an individual patient's unique neurological biomarkers. Combined with patients' genetic and medical history, NeuroKaire can improve selection of the optimal drug therapy for each patient. This opens the door to faster treatment, fewer side effects, and lower dosing, and the elimination of arduous trial-and-error treatment protocols and needless loss of life. NeuroKaire also enables pharmaceutical and biotechnology companies to bring precision medicine into drug development throughout the developmental pipeline across psychiatry and neurology.